source
- Lilly’s EloraTZP combo shows superior weight loss and glucose control, moves to Phase 3Eli Lilly reported that its experimental combination, EloraTZP, which pairs an amylin agonist with the approved obesity drug Zepbound, met all primary and secondary goals in a mid‑stage study of ad…
- Lilly's amylin-Zepbound combo shows 23% weight loss in type 2 diabetes patientsEli Lilly reported that its amylin‑Zepbound combination, eloraTZP, produced an average 23.3% weight loss in adults with type 2 diabetes who were also obese or overweight. The result was derived fro…